
Duloxetine
Duloxetine is an established SNRI used for both mood and pain. Network meta-analyses found it more effective than placebo for depression and generalized anxiety disorder, and Cochrane reviews found it the best-supported antidepressant for chronic pain, with moderate-quality evidence for diabetic nerve pain. St. John's wort is the critical supplement interaction, heavy alcohol use is a high-severity concern because of liver injury, and saffron is a low one.
Prescription medication: not a dietary supplement
This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only. It is not a recommendation to obtain or use it without a doctor.
Quick decision guide
May help most
Adults with major depression, generalized anxiety disorder, diabetic nerve pain, fibromyalgia or chronic musculoskeletal pain whose prescriber recommends an SNRI
Common dosing range
Set by your prescriber. Labeled doses are 30 to 60 mg once daily for most uses, with a label maximum of 120 mg a day for depression and anxiety and 60 mg a day for the pain conditions
When to expect effects
These are trial lengths, not when benefit starts: diabetic nerve pain results were measured at 12 weeks and fibromyalgia results at 12 and 28 weeks, chronic pain trials averaged 10 weeks, depression trials lasted a median of 8 weeks, and the label's adult anxiety trials lasted 9 to 10 weeks
Watch out for
Boxed warning for suicidal thoughts and behaviors in children, teens and young adults. Never combine with MAO inhibitors. Can cause liver injury, worse with heavy drinking. Raises serotonin syndrome risk with St. John's wort and bleeding risk with blood thinners and NSAIDs. Do not stop suddenly: the label recommends a gradual reduction set by your prescriber
What is it
Duloxetine is a prescription medicine of the serotonin and norepinephrine reuptake inhibitor (SNRI) class. It is sold as generic duloxetine delayed-release capsules and under the brand names Cymbalta and Drizalma Sprinkle. The Cymbalta label approves it for major depressive disorder in adults, generalized anxiety disorder in adults and children 7 and older, nerve pain from diabetes (diabetic peripheral neuropathic pain) in adults, fibromyalgia in adults and teens 13 and older, and chronic musculoskeletal pain in adults.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
major depressive disorder Good Evidence | Modest; response odds about 1.4 to 2.1 times placebo across antidepressants | Adults with moderate to severe major depression | Measured over acute treatment trials, typically about 8 weeks |
generalized anxiety disorder Good Evidence | Modest; about 3 points more improvement on the Hamilton Anxiety Scale than placebo | Adult outpatients with generalized anxiety disorder | Measured at the end of the included randomized trials |
diabetic peripheral neuropathic pain Good Evidence | Moderate; number needed to treat about 5 for halving pain | Adults with painful diabetic peripheral neuropathy | Measured at 12 weeks |
chronic pain (fibromyalgia, nerve and musculoskeletal pain) Good Evidence | Small to moderate; odds of substantial pain relief about 1.9 times placebo | Adults with fibromyalgia, neuropathic pain or chronic musculoskeletal pain | Trials averaged about 10 weeks |
fibromyalgia Limited Evidence | Small; number needed to treat about 8 | Adults with fibromyalgia | Measured at 12 and 28 weeks |
major depressive disorder
- Effect
- Modest; response odds about 1.4 to 2.1 times placebo across antidepressants
- Best fit
- Adults with moderate to severe major depression
- Time
- Measured over acute treatment trials, typically about 8 weeks
generalized anxiety disorder
- Effect
- Modest; about 3 points more improvement on the Hamilton Anxiety Scale than placebo
- Best fit
- Adult outpatients with generalized anxiety disorder
- Time
- Measured at the end of the included randomized trials
diabetic peripheral neuropathic pain
- Effect
- Moderate; number needed to treat about 5 for halving pain
- Best fit
- Adults with painful diabetic peripheral neuropathy
- Time
- Measured at 12 weeks
chronic pain (fibromyalgia, nerve and musculoskeletal pain)
- Effect
- Small to moderate; odds of substantial pain relief about 1.9 times placebo
- Best fit
- Adults with fibromyalgia, neuropathic pain or chronic musculoskeletal pain
- Time
- Trials averaged about 10 weeks
fibromyalgia
- Effect
- Small; number needed to treat about 8
- Best fit
- Adults with fibromyalgia
- Time
- Measured at 12 and 28 weeks
Evidence for 5 uses
AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.
major depressive disorder
Disease adjunctA 2018 network meta-analysis of 522 double-blind trials with 116,477 adults found that all 21 antidepressants studied, including duloxetine, were more effective than placebo for acute treatment of major depression, with odds ratios from 1.37 to 2.13. In head-to-head trials, duloxetine was among the drugs with the highest dropout rates. The authors rated the certainty of evidence moderate to very low overall.
Bottom line: Duloxetine works better than placebo for depression, with more dropouts than some alternatives.
generalized anxiety disorder
Disease adjunctA 2019 network meta-analysis of 89 randomized trials with 25,441 adult outpatients found duloxetine more effective than placebo for generalized anxiety disorder, lowering the Hamilton Anxiety Scale score by 3.13 points more (95% credible interval 2.13 to 4.13), with relatively good acceptability. Pregabalin, venlafaxine and escitalopram had similar effects.
Bottom line: Duloxetine is one of the more effective drugs for generalized anxiety, by a modest margin.
diabetic peripheral neuropathic pain
Disease adjunctA 2014 Cochrane review of 8 trials with 2,728 people with painful diabetic neuropathy found duloxetine 60 mg a day made a 50% or greater pain reduction at 12 weeks more likely than placebo (risk ratio 1.73, 95% CI 1.44 to 2.08), with about 1 extra person helped for every 5 treated. The authors rated the evidence moderate quality, noted that the trials were run by the manufacturer, and found doses below 60 mg a day not effective.
Bottom line: At 60 mg a day, duloxetine halves diabetic nerve pain for about 1 in 5 more people than placebo.
chronic pain (fibromyalgia, nerve and musculoskeletal pain)
Disease adjunctA 2023 Cochrane network meta-analysis of 176 trials with 28,664 adults compared 25 antidepressants for chronic pain. Duloxetine was consistently the highest-ranked, and at the standard 60 mg dose it had a small to moderate effect on substantial pain relief (odds ratio 1.91, 95% CI 1.69 to 2.17; moderate-certainty evidence), with high doses no better than standard doses. Trials averaged 10 weeks, mostly excluded people with low mood, and gave no reliable evidence on long-term benefit or safety.
Bottom line: Among antidepressants, duloxetine has the most reliable evidence for chronic pain, with modest effects.
fibromyalgia
Disease adjunctThe same Cochrane review pooled 6 fibromyalgia trials with 2,249 participants: duloxetine 60 mg a day made a 50% or greater pain reduction more likely over 12 weeks (risk ratio 1.57, 95% CI 1.20 to 2.06; number needed to treat 8) and over 28 weeks (risk ratio 1.58). The authors rated this lower-quality evidence and said the effect may come partly from improved mental symptoms rather than physical pain.
Bottom line: Duloxetine helps a minority of people with fibromyalgia, and the evidence is weaker than for nerve pain.
How it works
How to take it
What to track
Bottom line: Your prescriber sets the dose; swallow the capsule whole, keep alcohol low, and never stop suddenly on your own.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Suicidal thoughts and behaviors (boxed warning). Antidepressants increased these in children, teens and young adults in short-term studies; anyone taking duloxetine should be watched for worsening mood, especially early and after dose changes.
Liver injury, including liver failure that has sometimes been fatal. The label tells prescribers to discontinue duloxetine if jaundice or other clinically significant liver problems appear, and says it should ordinarily not be prescribed to people with substantial alcohol use or chronic liver disease. Report yellow skin or eyes, dark urine or upper-belly pain to your doctor promptly.
Serotonin syndrome, a potentially life-threatening reaction, especially with other serotonergic products (triptans, tricyclic antidepressants, opioids such as tramadol and fentanyl, lithium, tryptophan, buspirone, amphetamines, St. John's wort) or MAO inhibitors.
Dizziness on standing (orthostatic hypotension), falls and fainting, most often in the first week and after dose increases.
Higher risk of bleeding, greater with aspirin, NSAIDs, warfarin and other blood thinners.
Severe skin reactions, including erythema multiforme and Stevens-Johnson syndrome; the label says duloxetine should be discontinued at the first sign of blisters, peeling rash or mouth sores if no other cause is found, so contact your doctor right away if these appear.
Discontinuation symptoms, low blood sodium, raised blood pressure, higher blood sugar and HbA1c in people with diabetic nerve pain, seizures, activation of mania and angle-closure glaucoma.
Who should avoid it
- People taking an MAO inhibitor or within 14 days of stopping one, and people being treated with linezolid or intravenous methylene blue; at least 5 days must pass after stopping duloxetine before starting an MAOI
- People with substantial alcohol use, chronic liver disease or cirrhosis
- People with severe kidney impairment (GFR below 30 mL/minute)
- People taking thioridazine, which the label says should not be combined with duloxetine because of the risk of serious heart rhythm problems and sudden death
Pregnancy & breastfeeding
Pregnancy: the Cymbalta label says published data and a postmarketing cohort study have not identified a clear drug-associated risk of major birth defects or other adverse developmental outcomes. Use in the month before delivery may be associated with a higher risk of heavy bleeding after birth, and babies exposed late in the third trimester have had breathing, feeding and temperature problems needing hospital care. Untreated depression and fibromyalgia also carry risks in pregnancy. Breastfeeding: duloxetine passes into breast milk (in 6 women, the estimated infant dose was less than 1% of the maternal dose), and there are reports of sedation, poor feeding and poor weight gain in exposed infants; the label says to weigh the benefits of breastfeeding against the mother's need for treatment and to monitor the infant.
Interactions
The Cymbalta label lists St. John's wort among serotonergic products that increase the risk of serotonin syndrome, a potentially life-threatening reaction, when combined with duloxetine. Do not combine them without your prescriber's advice, and if you already take both, contact your prescriber rather than stopping anything on your own. Seek emergency care for agitation, tremor, fever, fast heartbeat, heavy sweating or muscle stiffness.
The Cymbalta label says combining duloxetine with tryptophan, the amino acid the body turns into serotonin, increases the risk of serotonin syndrome, a potentially life-threatening reaction, and its Medication Guide names over-the-counter tryptophan supplements. No case with only this pair has been published. Do not add a tryptophan supplement unless your prescriber advises it, and seek emergency care for agitation, tremor, fever, fast heartbeat, heavy sweating or muscle stiffness.
5-HTP is the body's direct building block for serotonin, so it adds to duloxetine's serotonin effect. The Cymbalta label names tryptophan, the amino acid the body turns into 5-HTP, among products that increase the risk of serotonin syndrome; it does not name 5-HTP itself, and no duloxetine case has been published. Do not combine them unless your prescriber directs it, and seek emergency care for agitation, tremor, fever, fast heartbeat, heavy sweating or muscle stiffness.
Contraindicated because of the risk of serotonin syndrome. The label requires at least 14 days after stopping an MAOI before starting duloxetine, and at least 5 days after stopping duloxetine before starting an MAOI.
The label warns that duloxetine with heavy alcohol intake may be associated with severe liver injury, and says it should not be prescribed to people with substantial alcohol use. In a lab study, duloxetine did not worsen alcohol's effects on thinking and coordination; the concern is the liver. Be honest with your prescriber about how much you drink, and report yellow skin or eyes, dark urine or upper-belly pain promptly.
The label says to avoid combining duloxetine with potent CYP1A2 inhibitors. Fluvoxamine raised duloxetine exposure about 6-fold in a study, and the label names cimetidine and quinolone antibiotics such as ciprofloxacin as other CYP1A2 blockers. Make sure every prescriber knows you take duloxetine before a new medicine is added.
Drugs that affect serotonin reuptake, including duloxetine, can increase bleeding, and the label says NSAIDs, aspirin and anticoagulants may add to this risk; altered warfarin effects, including increased bleeding, have been reported. Ask your pharmacist before using an over-the-counter pain reliever.
Saffron may act partly on serotonin, which raises a theoretical concern about added effects with duloxetine. In an 8-week trial of 160 adults already taking an antidepressant, adding a standardized saffron extract improved clinician-rated depression scores and did not worsen antidepressant side effects; results for duloxetine users were not reported separately. Discuss it with your prescriber before using a saffron supplement.
Documented interactions
Evidence-graded pair pages with sources, dosing notes, and timing guidance, a complement to the narrative section above.
Warnings (4)
+ 5-htp
criticalDuloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that keeps serotonin active longer, and 5-HTP (5-hydroxytryptophan) is the direct building block the body turns into serotonin, so taking both can push serotonin activity too high and cause serotonin syndrome, a potentially life-threatening reaction. The Cymbalta label names tryptophan, the amino acid the body turns into 5-HTP, among serotonergic drugs that increase this risk; it does not name 5-HTP itself. No case with duloxetine and 5-HTP was found; the concern rests on the label, the shared mechanism and a published case of serotonin syndrome when 5-HTP was taken with sertraline, an SSRI.
+ st. john's wort
criticalDuloxetine and St. John's wort both increase serotonergic activity, and combining them can raise serotonin to levels associated with serotonin syndrome, a potentially life-threatening reaction. The duloxetine label lists St. John's Wort among the drugs that raise this risk.
+ tryptophan
criticalDuloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that keeps serotonin active longer, and L-tryptophan is the amino acid the body turns into serotonin, so taking both can push serotonin activity too high. The Cymbalta label says combining duloxetine with other serotonergic drugs, naming tryptophan in the same list as St. John's wort, increases the risk of serotonin syndrome, a potentially life-threatening reaction. No published case with only this pair was found; the rating follows the label warning and matches the rating for tryptophan with venlafaxine, the other SNRI, and with SSRIs such as sertraline and fluoxetine.
+ alcohol
highDuloxetine (Cymbalta) can occasionally cause liver injury, and liver failure, sometimes fatal, has been reported. Its FDA label says that because duloxetine and alcohol may interact to cause liver injury, it should not be prescribed to people with substantial alcohol use or evidence of chronic liver disease, and that heavy alcohol intake with duloxetine may be associated with severe liver injury. In a study described on the label, duloxetine did not add to alcohol's impairment of thinking and coordination; the concern is the liver.
Choosing a product
What to look for on the label, and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
Can I take St. John's wort with duloxetine?⌄
This page rates it a critical interaction. The Cymbalta label lists St. John's wort among products that raise the risk of serotonin syndrome with duloxetine. Talk to your prescriber before using it, and if you have been combining them, contact your prescriber rather than stopping anything on your own.
Can I drink alcohol while taking duloxetine?⌄
This page rates heavy drinking with duloxetine a high-severity interaction. The label warns that duloxetine with heavy alcohol intake may be associated with severe liver injury and says it should not be prescribed to people with substantial alcohol use. Be honest with your prescriber about how much you drink.
Is saffron safe with duloxetine?⌄
The concern is theoretical. In a trial of adults already on antidepressants, adding saffron did not worsen side effects, but duloxetine users were not reported separately. This page rates it low severity. Ask your prescriber before starting a saffron supplement.
Can I take ibuprofen with duloxetine?⌄
The label says NSAIDs such as ibuprofen and naproxen, aspirin and blood thinners may add to duloxetine's bleeding risk. Ask your pharmacist before using an over-the-counter pain reliever, especially if you take it often.
Can I open the capsule and mix it with food?⌄
Not for Cymbalta or generic duloxetine capsules. The label says to swallow them whole and not to chew, crush or sprinkle the contents on food, which can damage the coating. If swallowing is hard, ask your prescriber or pharmacist about options.
What happens if I stop duloxetine suddenly?⌄
Stopping can cause symptoms such as dizziness, headache, nausea, irritability and trouble sleeping. The label recommends a gradual reduction rather than stopping abruptly. Talk to your prescriber before making any change.
References by claim
major depressive disorder
Cipriani et al., 2018 · PMC (2018) link
generalized anxiety disorder
Slee et al., 2019 · PubMed (2019) link
diabetic peripheral neuropathic pain
Lunn et al., 2014 · PMC (2014) link
chronic pain (fibromyalgia, nerve and musculoskeletal pain)
Birkinshaw et al., 2023 · PMC (2023) link
Safety
Cymbalta (duloxetine delayed-release capsules) prescribing information · DailyMed (FDA label) link
Interaction: 5-HTP (5-hydroxytryptophan)
Patel et al., 2017 · PMC (2017) link
Interaction: Saffron (supplements)
Lopresti et al., 2019 · PubMed (2019) link
Track Duloxetine with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora app.
Disclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.
